Latest Pharma News
Follow the latest pharma news from India and the wider pharmaceutical industry. This section highlights major headlines, breaking developments, and important daily updates.
-
Single-Use Becomes the CGT Baseline
Single-Use Becomes the CGT Baseline Contract Pharma
-
Cracked gaskets and rust-like residues trigger FDA warning letter to Alchymars
Cracked gaskets and rust-like residues trigger FDA warning letter to Alchymars BioSpace
-
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies PR Newswire
-
Pharma Roundup: Mounjaro Shows Advantages in Type 2 Diabetes, Immune System Linked to Long Covid Symptoms
Pharma Roundup: Mounjaro Shows Advantages in Type 2 Diabetes, Immune System Linked to Long Covid Symptoms PharmExec.com
-
Pfizer, Innovent strike $10B cancer drug deal
Pfizer, Innovent strike $10B cancer drug deal BioPharma Dive
Regulatory Updates
Track pharmaceutical regulatory updates, policy changes, and compliance-related news. This section is useful for staying informed about approvals, guidelines, and official announcements.
-
AstraZeneca’s Imfinzi Approved by FDA for BCG-Naïve Non-Muscle-Invasive Bladder Cancer
AstraZeneca’s Imfinzi Approved by FDA for BCG-Naïve Non-Muscle-Invasive Bladder Cancer Contract Pharma
-
Replimune to resubmit melanoma drug RP1 after FDA shakeup
Replimune to resubmit melanoma drug RP1 after FDA shakeup qz.com
-
Can a chaotic FDA still deliver on faster drug development?
Can a chaotic FDA still deliver on faster drug development? BioPharma Dive
-
Replimune gets third chance at US approval for skin cancer drug
Replimune gets third chance at US approval for skin cancer drug Reuters
-
Pharmalittle: We're reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
Pharmalittle: We're reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more statnews.com
Drug Approvals
Read about new drug approvals, product clearances, and important authorisations. This section covers medicines entering the market and other notable approval milestones.
-
Fact vs. Fallacy: Challenging the Norms of Cancer Care
Fact vs. Fallacy: Challenging the Norms of Cancer Care Medscape
-
Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer PR Newswire
-
New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma
New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma The Manila Times
-
12M Americans have BPH; one biotech is testing a plant-based option
12M Americans have BPH; one biotech is testing a plant-based option Stock Titan
-
CSPC Wins China Approval for New HER2-Targeting Cancer Drug Ennituo
CSPC Wins China Approval for New HER2-Targeting Cancer Drug Ennituo TipRanks
Clinical and Research Updates
Explore clinical trial news, research findings, and developments in pharmaceutical science. This section focuses on innovation, studies, and progress in drug development.
-
An experimental GLP-1 pushes the limits of weight loss. There are risks.
An experimental GLP-1 pushes the limits of weight loss. There are risks. The Washington Post
-
Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions
Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions The Manila Times
-
World-First Focused Ultrasound Equine Clinical Trial Underway | Newswise
World-First Focused Ultrasound Equine Clinical Trial Underway | Newswise Newswise
-
Weekly Rundown: Oxford scientists develop rapid Ebola vaccine as Congo outbreak grows
Weekly Rundown: Oxford scientists develop rapid Ebola vaccine as Congo outbreak grows Drug Discovery News
-
Can AI crack pharma’s drug repurposing goldmine?
Can AI crack pharma’s drug repurposing goldmine? Pharma Voice
Industry Events
Discover pharma conferences, exhibitions, seminars, and industry events in India. This section helps readers keep track of sector gatherings and professional events.
-
"Keralam to be South Asia's largest aviation hub; Govt to dismantle drug mafias": CM VD Satheesan
"Keralam to be South Asia's largest aviation hub; Govt to dismantle drug mafias": CM VD Satheesan India's News.Net
-
Simplification, standardisation & AI-enabled industry: Veeva R&D and Quality Summit 2026
Simplification, standardisation & AI-enabled industry: Veeva R&D and Quality Summit 2026 pharmaphorum
-
GrowQR Takes the Stage at Bihar AI Summit 2026, Announces GCC Plans for the State
GrowQR Takes the Stage at Bihar AI Summit 2026, Announces GCC Plans for the State Big News Network.com
-
Investment Gateway Summit 2026 Returns to St. Kitts and Nevis for 3rd edition
Investment Gateway Summit 2026 Returns to St. Kitts and Nevis for 3rd edition Big News Network.com
Company Announcements
View company announcements including results, partnerships, expansions, and strategic updates. This section offers insights into the latest moves by pharma businesses.
-
Veeva Systems' AI & Vault CRM Strength Signal More Upside Ahead
Veeva Systems' AI & Vault CRM Strength Signal More Upside Ahead qz.com
Market and Sector Headlines
Stay informed on market trends, sector performance, and broader industry headlines. This section gives a wider view of the forces shaping the pharmaceutical market.
-
Evotec SE stock (DE0005664809): valuation in focus after May voting-rights update
Evotec SE stock (DE0005664809): valuation in focus after May voting-rights update AD HOC NEWS
-
Ryvu Therapeutics S.A. stock (PLRVVEL00018): shares steady in Warsaw as investors digest recent fina
Ryvu Therapeutics S.A. stock (PLRVVEL00018): shares steady in Warsaw as investors digest recent fina AD HOC NEWS
-
Richter Gedeon Nyrt. stock (HU0000123096): shares steady as Budapest pharma name digests recent divi
Richter Gedeon Nyrt. stock (HU0000123096): shares steady as Budapest pharma name digests recent divi AD HOC NEWS
-
Lexicon Pharmaceuticals stock (US5396941031): Nasdaq-listed biotech highlights upcoming conference p
Lexicon Pharmaceuticals stock (US5396941031): Nasdaq-listed biotech highlights upcoming conference p AD HOC NEWS
-
AI takes on brain cancer: how NeOnc targets the blood-brain barrier
AI takes on brain cancer: how NeOnc targets the blood-brain barrier Stock Titan
Policy and Government Initiatives
This section covers new regulations, industry support measures, and reforms that affect manufacturing, pricing, and compliance. It is also useful for following government schemes that encourage domestic production, exports, and research-led growth.
-
Existing labour laws not aligned with e-commerce economy, need redesign for gig workers' welfare: Policy expert
Existing labour laws not aligned with e-commerce economy, need redesign for gig workers' welfare: Policy expert India's News.Net
-
Green India Challenge Showcases Citizen-Led Climate Federalism Model at IIM Bangalore Climate Innovation Summit 2026
Green India Challenge Showcases Citizen-Led Climate Federalism Model at IIM Bangalore Climate Innovation Summit 2026 India's News.Net
-
'Sit down and fix policy...': JPMorgan Chase CEO Jamie Dimon reveals his warning to NYC Mayor Zohran Mamda
'Sit down and fix policy...': JPMorgan Chase CEO Jamie Dimon reveals his warning to NYC Mayor Zohran Mamda The Economic Times
-
Evolving Health Landscape: Key Developments in Global Health Policies
Evolving Health Landscape: Key Developments in Global Health Policies Devdiscourse
-
Dharmendra Pradhan Defends CBSE's Three-Language Policy, Says Daughter Studied Marathi Till Class 8
Dharmendra Pradhan Defends CBSE's Three-Language Policy, Says Daughter Studied Marathi Till Class 8 NDTV Profit